Edison Pharmaceuticals Inks $20M Series F


Edison Pharmaceuticals has closed a $20 million Series F round, the company announced. Mitsui & Co. Global Investment Inc. led the financing. The money will go toward clinical development of the company’s products.

PRESS RELEASE

Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment, Inc. led the financing and will occupy a board of directors seat.

Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich’s ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.

Edison Pharmaceuticals

Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases.

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.